Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension.

Briot K, Portale AA, Brandi ML, Carpenter TO, Cheong HI, Cohen-Solal M, Crowley RK, Eastell R, Imanishi Y, Ing S, Insogna K, Ito N, Jan de Beur S, Javaid MK, Kamenicky P, Keen R, Kubota T, Lachmann RH, Perwad F, Pitukcheewanont P, Ralston SH, Takeuchi Y, Tanaka H, Weber TJ, Yoo HW, Nixon A, Nixon M, Sun W, Williams A, Imel EA

Open source

DOI: 10.1136/rmdopen-2021-001714
Published: 2021 Sep
Container: RMD open
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/rmdopen-2021-001714,
  title = {Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension.},
  author = {Briot K and Portale AA and Brandi ML and Carpenter TO and Cheong HI and Cohen-Solal M and Crowley RK and Eastell R and Imanishi Y and Ing S and Insogna K and Ito N and Jan de Beur S and Javaid MK and Kamenicky P and Keen R and Kubota T and Lachmann RH and Perwad F and Pitukcheewanont P and Ralston SH and Takeuchi Y and Tanaka H and Weber TJ and Yoo HW and Nixon A and Nixon M and Sun W and Williams A and Imel EA},
  year = {2021},
  journal = {RMD open},
  doi = {10.1136/rmdopen-2021-001714},
  url = {https://doi.org/10.1136/rmdopen-2021-001714}
}

RIS

TY  - JOUR
TI  - Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension.
AU  - Briot K
AU  - Portale AA
AU  - Brandi ML
AU  - Carpenter TO
AU  - Cheong HI
AU  - Cohen-Solal M
AU  - Crowley RK
AU  - Eastell R
AU  - Imanishi Y
AU  - Ing S
AU  - Insogna K
AU  - Ito N
AU  - Jan de Beur S
AU  - Javaid MK
AU  - Kamenicky P
AU  - Keen R
AU  - Kubota T
AU  - Lachmann RH
AU  - Perwad F
AU  - Pitukcheewanont P
AU  - Ralston SH
AU  - Takeuchi Y
AU  - Tanaka H
AU  - Weber TJ
AU  - Yoo HW
AU  - Nixon A
AU  - Nixon M
AU  - Sun W
AU  - Williams A
AU  - Imel EA
PY  - 2021
JO  - RMD open
DO  - 10.1136/rmdopen-2021-001714
UR  - https://doi.org/10.1136/rmdopen-2021-001714
ER  -

APA

K, B., AA, P., ML, B., TO, C., HI, C., M, C., RK, C., R, E., Y, I., S, I., K, I., N, I., S, J. D. B., MK, J., P, K., R, K., T, K., RH, L., F, P., P, P., SH, R., Y, T., H, T., TJ, W., HW, Y., A, N., M, N., W, S., A, W., & EA, I. (2021). Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension.. RMD open. https://doi.org/10.1136/rmdopen-2021-001714

Source records

pubmed · retrieved 2026-09-25T11:56:52.106Z